Top Health Tech Companies in Raleigh, NC (77)

Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.

Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.

Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.

Strong Revenue Growth: Revenue is rising at a double‑digit pace across 2025 and into 2026, with consistent year‑over‑year gains. Galleri test volumes and screening revenue also increased, signaling sustained commercial momentum.

Market Expansion: Access is broadening through major EHR integrations and a growing provider network, alongside initiatives to enter new geographies. These moves extend reach beyond core channels and support continued adoption.

Investor Backing & Capital Strength: Capital raises and a sizable cash position provide a multi‑year runway to fund commercialization, trials, and regulatory efforts. Strategic financings with prominent partners reinforce the ability to invest through scale‑up.

Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.

Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.

Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.

Investor Backing & Capital Strength: Recent $300M financing in March 2026, conversion to a C‑corp, and Alphabet remaining a significant minority investor indicate strong capital access to scale its AI‑native precision health platform. Earlier large rounds and ongoing backing provide resources for expansion while pursuing independence.

Product Line Growth: The company has expanded offerings with the AI‑native Pre platform (including opening Exchange and Workbench self‑serve/free tiers), the Verily Me app, and the Lightpath Metabolic program positioned for broad availability in 2026. These launches and migrations from Onduo signal a cohesive product strategy aimed at broader adoption.

Strategic Partnerships: Partnerships with NVIDIA, Samsung, UCHealth/CU Anschutz, and NIH “All of Us” via Vanderbilt, plus CMS ACCESS model participation, point to growing ecosystem traction. These collaborations expand research and care use cases and distribution channels.

Strong Revenue Growth: Leadership reports the business has doubled since pivoting fully to long‑term, high‑acuity home nursing, with sustained rapid expansion over multiple years. De novo openings and acquisitions are consistently cited as contributing meaningfully to ongoing growth.

Market Expansion: The company has expanded from a single operation to a multi‑state footprint with dozens of offices, entering new geographies via partnerships and acquisitions. Announcements highlight a steady cadence of new branch launches and integrations that extend its national reach.

Innovation-Driven Growth: Development of CareSightAI and emphasis on value‑based arrangements are credited with reducing avoidable hospitalizations and strengthening performance with managed care payers. Distinctive programs like the Parent/Family CNA model are promoted as differentiated offerings that support growth.

Strong Market Position & Advantage: Invisalign is broadly viewed as the clear leader in doctor‑directed clear aligners, reinforced by a large trained‑doctor base and an integrated digital workflow. Record Q4/FY 2025 volumes and revenue, alongside industry characterization as the market leader, support advantage durability.

Market Expansion: International regions (EMEA, Latin America, APAC) are cited as driving year‑over‑year volume growth, with contributions from teen/kids and adult segments and growing DSO/OSO channels. Continued gains outside North America align with guidance for additional growth into 2026.

Innovation-Driven Growth: An integrated platform spanning Invisalign, iTero scanners, and exocad software underpins a closed‑loop workflow that encourages adoption. Ongoing iTero Lumina upgrades and plans for directly 3D‑printed retainers/attachments in 2026 indicate a pipeline that can sustain future growth.

Strong Revenue Growth: Revenue is rising at a double‑digit pace across recent quarters and the latest fiscal year, with momentum reflected in higher quarterly results and a raised full‑year outlook. Near‑term guidance also points to continued expansion through the remainder of the year.

Profitability: Profitability has expanded alongside growth, with operating income and earnings increasing meaningfully in the latest quarter. A subscription‑heavy mix and higher full‑year operating income guidance support margin durability.

Strong Market Position & Advantage: Position in life‑sciences CRM remains dominant, with a very large share of biopharma seats cited by management and many top‑20 pharmas live on next‑gen Vault CRM. Broad adoption across Development and Quality Clouds and continued big‑pharma commitments reinforce competitive advantage.

Strong Market Position & Advantage: Dominant leadership is reinforced by being a pioneer in robotic-assisted surgery and maintaining a large, entrenched installed base that drives broad adoption. Competitive moats are further supported by surgeon training and ecosystem stickiness tied to hospital investments and workflow standardization.

Strong Revenue Growth: Revenue is described as growing strongly year over year, alongside sustained multi-year growth and forward projections that indicate continued expansion. Procedure volumes are also rising at a double-digit pace, supporting ongoing demand for the core platform.

Diversified Revenue Streams: A large share of revenue is characterized as recurring, driven by instruments, accessories, services, and usage tied to procedure volume rather than one-time system sales. This mix supports a steadier business profile as the installed base expands.

Strong Market Position & Advantage: Roche is the global leader in in‑vitro diagnostics and remains a top‑tier biopharma with a significant oncology footprint. The dual Pharmaceuticals–Diagnostics model is a strategic differentiator at scale.

Strong Revenue Growth: Group sales rose 7% at constant exchange rates in 2025 and 6% at CER in Q1 2026, with both divisions contributing. Guidance for 2026 indicates continued mid–single‑digit CER growth.

Profitability: Profitability improved in 2025 alongside sales, with higher IFRS net income and core EPS growth. Management pointed to capacity to keep investing while rewarding shareholders.

Strong Market Position & Advantage: The company is positioned as a top-tier global CRO with significant scale and a broad geographic footprint, supported by a major acquisition that strengthened its competitive standing. Operational activity indicators and industry recognition are presented as reinforcing its ability to win and execute large, complex trials.

Profitability: Earnings and operating profit metrics are described as improving in 2024, with increases in GAAP net income, adjusted earnings per share, and adjusted EBITDA. These results suggest the business maintained solid margin performance even as quarterly revenue fluctuated.

Resilient & Sustainable Growth: A large backlog and a book-to-bill above 1.0 in 2024 are cited as providing multi-year revenue visibility and demand coverage. Continued backlog levels into 2025 are described as a stabilizing factor despite a softer near-term revenue trajectory.